---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-301206"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:10:11.989498+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Dianthus recasts audited financials for legacy OpCo; net loss $28.5M in 2022, going concern noted

## Summary
- Net loss of $28.5M in 2022, $13.1M in 2021; accumulated deficit $45.9M at Dec 31, 2022.
- Revenue from related party Zenas $6.4M in 2022, $1.5M in 2021; R&D expense $29.4M.
- Cash and investments $75.5M; going concern doubt due to insufficient capital for 12 months.
- Merger with Magenta closed Sep 11, 2023, accounted as reverse recapitalization; all historical shares restated at 0.2181 exchange ratio.

## SEC filing metadata
- accession: 0001193125-23-301206
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312523301206/0001193125-23-301206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523301206/d639778d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-301206
- JSON: https://secwatch.observer/filing/0001193125-23-301206.json
- Plain text: https://secwatch.observer/filing/0001193125-23-301206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.